Caris & Co Initiates Coverage on Wyeth (WYE) with an Above Average
More News related to WYE
- Citi Initiates Coverage on Wyeth (WYE) with a Hold
- Wyeth and Impax Announce Final Settlement of Effexor XR Patent Suit
- Telemedicus Engages VP for Sales & Marketing
- Study Showed Half of Patients Treated with Enbrel(R) (etanercept) Plus Methotrexate Can Achieve DAS Clinical Remission and 80 Percent Had No Progression of Joint Damage in Active Early Rheumatoid Arth
- Wyeth (WYE) Consumer Healthcare Agrees to Buy ThermaCare(R) from Procter & Gamble
Caris & Co initiates coverage on Wyeth (NYSE: WYE) with an Above Average rating. Price target $48.
Wyeth is engaged in the discovery, development, manufacture, distribution and sale of a line of products in three primary businesses: Wyeth Pharmaceuticals (Pharmaceuticals), Wyeth Consumer Healthcare (Consumer Healthcare), and Fort Dodge Animal Health (Animal Health).
Related Categories
New CoverageStocks Mentioned
-0.42Sign up for StreetInsider Free!
Recieve full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
